ATHE PE Ratio & Valuation, Is ATHE Overvalued

Historical Valuation

Alterity Therapeutics Ltd (ATHE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 48.42 is considered Overvalued compared with the five-year average of -19.92. The fair price of Alterity Therapeutics Ltd (ATHE) is between 0.65 to 2.64 according to relative valuation method. Compared to the current price of 3.55 USD , Alterity Therapeutics Ltd By Overvalued By 34.28%.

Relative Value

Fair Zone

0.65-2.64

Current Price：3.55

34.28%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Alterity Therapeutics Ltd (ATHE) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Alterity Therapeutics Ltd (ATHE) has a current Price-to-Book (P/B) ratio of 1.21. Compared to its 3-year average P/B ratio of 900.95, the current P/B ratio is approximately -99.87% higher. Relative to its 5-year average P/B ratio of 537.16, the current P/B ratio is about -99.77% higher. Alterity Therapeutics Ltd (ATHE) has a Forward Free Cash Flow (FCF) yield of approximately -25.41%. Compared to its 3-year average FCF yield of -56.42%, the current FCF yield is approximately -54.96% lower. Relative to its 5-year average FCF yield of -48.63%, the current FCF yield is about -47.75% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ATHE competitors is 17.15, providing a benchmark for relative valuation. Alterity Therapeutics Ltd Corp (ATHE.O) exhibits a P/S ratio of 50.59, which is 194.96% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ATHE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ATHE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ATHE currently overvalued or undervalued?

Alterity Therapeutics Ltd (ATHE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 48.42 is considered Overvalued compared with the five-year average of -19.92. The fair price of Alterity Therapeutics Ltd (ATHE) is between 0.65 to 2.64 according to relative valuation method. Compared to the current price of 3.55 USD, Alterity Therapeutics Ltd is Overvalued By 34.28%.

What is Alterity Therapeutics Ltd (ATHE) fair value?

ATHE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Alterity Therapeutics Ltd (ATHE) is between 0.65 to 2.64 according to relative valuation method.

How does ATHE's valuation metrics compare to the industry average?

The average P/S ratio for ATHE's competitors is 17.15, providing a benchmark for relative valuation. Alterity Therapeutics Ltd Corp (ATHE) exhibits a P/S ratio of 50.59, which is 194.96% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Alterity Therapeutics Ltd (ATHE) as of Apr 03 2026?

As of Apr 03 2026, Alterity Therapeutics Ltd (ATHE) has a P/B ratio of 1.21. This indicates that the market values ATHE at 1.21 times its book value.

What is the current FCF Yield for Alterity Therapeutics Ltd (ATHE) as of Apr 03 2026?

As of Apr 03 2026, Alterity Therapeutics Ltd (ATHE) has a FCF Yield of -25.41%. This means that for every dollar of Alterity Therapeutics Ltd's market capitalization, the company generates -25.41 cents in free cash flow.

What is the current Forward P/E ratio for Alterity Therapeutics Ltd (ATHE) as of Apr 03 2026?

As of Apr 03 2026, Alterity Therapeutics Ltd (ATHE) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Alterity Therapeutics Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Alterity Therapeutics Ltd (ATHE) as of Apr 03 2026?

As of Apr 03 2026, Alterity Therapeutics Ltd (ATHE) has a Forward P/S ratio of 48.42. This means the market is valuing ATHE at $48.42 for every dollar of expected revenue over the next 12 months.

ATHE Valuation